Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA) Written by PR Newswire The specified story doesn't exist 20260727223734EDT_image_1.jpg?id=OA2797270&p=medium600#Read more http://www.prnasia.com/story/archive/5013519_AE13519_0